<DOC>
	<DOCNO>NCT01255761</DOCNO>
	<brief_summary>Phase 4 study evaluate routine patient complete assessment ( RAPID3 ) compare physician complete assessment ( CDAI ) predict treatment success subject moderate severe rheumatoid arthritis</brief_summary>
	<brief_title>A Comparison Two Assessment Tools Predicting Treatment Success Cimzia Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description>RA0064 Phase 4 , multicenter , randomize , 52-week study . All eligible subject receive open label Cimzia 400 mg Weeks 0 , 2 4 , follow Cimzia 200 mg every 2 week Weeks 6 50 treatment moderate severe rheumatoid arthritis . All subject assess use 2 assessment tool : subject-based Routine Assessment Patient Index ( RAPID3 ) investigator-based Clinical Disease Activity Index ( CDAI )</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects 18 year age old Subjects diagnosis Adultonset Rheumatoid Arthritis least 3 month define 1987 American College Rheumatology ( ACR ) classification criterion Subjects active Rheumatoid Arthritis define : 4 tender joint ( 28 joint count ) Screening Baseline Visits ; 4 swollen joint ( 28 joint count ) Screening Baseline Visits Subjects unsatisfactory response intolerance least 1 traditional Diseasemodifying Antirheumatic Drugs ( DMARD ) Subjects must diagnosis inflammatory Arthritis Subjects must great 3 Arthroplasties due Rheumatoid Arthritis and/or Steinbrocker IV Functional Capacity Subjects must secondary noninflammatory type Arthritis would interfere study evaluation Subjects must diagnose Fibromyalgia sufficient symptom require treatment Subjects must history Infected Joint Prosthesis Subjects must discontinue biological therapy Rheumatoid Arthritis due Severe Hypersensitivity Reaction Anaphylactic Reaction Subjects must receive 2 anti Tumor Necrosis Factor ( TNF ) agents prior enrollment Subjects must receive treatment Abatacept and/or Rituximab receive experimental approve B cell therapeutic agent Subjects must history chronic alcohol drug abuse Subjects must know hypersensitivity component investigational medicinal product Subjects must history chronic infection , recent serious lifethreatening infection within 6 month current sign symptom may indicate infection Subjects must history Blood Dyscrasias Subjects know Tuberculosis ( TB ) Disease , high risk acquire TB latent TB infection Subjects must high risk infection Subjects must history Lymphoproliferative Disorder include Lymphoma sign symptom suggestive Lymphoproliferative Disease Subjects must concurrent acute chronic Viral Hepatitis B C Subjects must know Human Immunodeficiency Virus ( HIV ) infection Subject must concurrent Malignancy history Malignancy Subjects must current recent history severe , progressive , and/or uncontrolled Renal , Hepatic , Hematological , Gastrointestinal , Endocrine , Pulmonary , Cardiac , Neurological Cerebral Disease Subjects must Class III IV Congestive Heart Failure Subjects must history , suspect Demyelinating Disease Central Nervous System Subjects must history adverse reaction Polyethylene Glycol ( PEG ) Subjects must significant laboratory abnormality investigator judgment would make subject unsuitable inclusion Subjects must know history clinically active infection Histoplasma , Coccidiodes , Paracoccidioides , Pneumocystis , Nontuberculous Mycobacteria , Blastomyces Aspergillus Subject must know history currently diagnose Systemic Lupus Erythematosus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>CDAI</keyword>
	<keyword>RAPID3</keyword>
</DOC>